Press release: STADA sees strong sales and earnings growth in H1
One document
more
Stories from Bad
- Language:
- Media:
- Period:
- Period:Total
Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
One documentmorePress Release : STADA brings in Henshaw from Biogen to head Specialty as Kim leads Western Europe
One documentmorePress Release: STADA’s continued, resilient growth leads to record earnings in Q1
One documentmore- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
One documentmore Press Release: STADA sets course for the future - experienced healthcare manager Andreas Fibig to become Chairman of the Board
One documentmore
Press Release: STADA welcomes Ingo Schachel as Head of Investor Relations
One documentmorePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
morePress release: STADA continues strong growth journey in the first half of 2024
One documentmorePress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmore
Press release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmorePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmore- 3
Press release: STADA further improves Sustainability ranking; rates among top 6% of pharma players globally
One documentmore Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio
One documentmore
- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care to acquire NxStage Medical, Inc. to strengthen its vertically integrated dialysis business
Bad Homburg (ots) - Acquisition of NxStage Medical, Inc. would: - position Fresenius Medical Care as a global leader in home dialysis - establish U.S. presence in the critical care space - further enhance clinical outcomes and patient empowerment - support strategic initiative of vertical integration and Care ...
moreNew UK sales subsidiary for Dr. Hauschka: WALA UK Ltd.
Bad Boll/Eckwälden (ots) - Dr. Hauschka, a brand marketed by the traditional German company WALA Heilmittel GmbH, is now able to boost its presence on the UK market. A newly established subsidiary, WALA UK Ltd., which is based in Oxfordshire near London, will be marketing and distributing the premium natural and organic cosmetics products as of 1 January. Dr. Hauschka enthusiasts will be able to find a wide range of ...
moreTop location in Milan - Dr. Hauschka flagship store opens its doors (BILD)
moreEANS-Tip Announcement: Syzygy AG / Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG (the German Securities Act) with the objective of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
more
EANS-Voting Rights: Syzygy AG / Correction of a release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution from Feb 15, 2012 at 15:16
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Correction of a release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution from Jan 16, 2013 at 09:24
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-News: SYZYGY Group wins BMW-account
company: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English ...
moreEANS-Adhoc: SYZYGY AG / Dividend proposal of EUR 0.25 per share
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English ...
moreEANS-Voting Rights: Syzygy AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
more
12Next